Enanta’s next RSV pill raises ‘high bar set by zelicapavir’

US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors.

The Boston-based biotech has announced positive top-line results from a Phase IIa human challenge study of EDP-323 in healthy adults infected with RSV.

These data demonstrated that EDP-323 was generally safe and well-tolerated and achieved an 85-87% reduction in viral load area under the curve (AUC), a 97-98% reduction in infectious viral load AUC by viral culture, and a 66-78% reduction of total clinical symptoms score AUC compared to placebo.